GNF6702 is the name for a broad-spectrum
antiprotozoal drug invented by researchers working at the Genomics Institute of the
Novartis Research Foundation in 2013,[1] with activity against
leishmaniasis,
Chagas disease and
sleeping sickness. These three diseases are caused by related
kinetoplastidparasites, which share similar biology. GNF6702 acts as
allostericproteasome inhibitor which was effective against infection with any of the three protozoal diseases in mice, while having little evident toxicity to mammalian cells.[2]
^US 2015175613, Biggart A, et al., "Compounds and compositions for the treatment of parasitic diseases", published 25 June 2015, assigned to Novartis AG